G
Gyre Therapeutics, Inc. (GYRE)
NCM – Real Time Price. Currency in USD
6.29
+0.06 (0.96%)
At close: Jun 26, 2026, 4:00 PM EDT
6.34
+0.05 (0.79%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.29
+0.06 (0.96%)
At close: Jun 26, 2026, 4:00 PM EDT
6.34
+0.05 (0.79%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
| Name | Position |
|---|---|
| Dr. Ying Luo Ph.D. | CEO, President & Director |
| Dr. Yue Xiong Ph.D. | Chief Scientific Officer |
| Jing Liu Ph.D. | Senior Vice President of Platform Chemistry |
| Mark Marino | Senior Vice President of Clinical Development |
| Mr. Jialiang Wang Ph.D. | Executive VP & GM |
| Mr. Joshua Bergmann J.D. | General Counsel & Corporate Secretary |
| Mr. Thomas W. Eastling M.D. | Chief Financial Officer |
| Mr. Weiguo Ye | Chief Operating Officer |
| Ms. Ruoyu Chen | Chief Information Officer |
| Seth Goldblum M.B.A. | Senior Vice President of Corporate Development |
| Date | Type | Document |
|---|---|---|
| 2026-06-23 | S-3 | ny20070577x1_s3.htm |
| 2026-06-16 | 8-K | ef20076059_8k.htm |
| 2026-06-10 | S-8 | ef20075357_s8.htm |
| 2026-06-02 | 8-K | ef20075381_8k.htm |
| 2026-05-14 | 8-K | ef20073544_8k.htm |
| 2026-05-12 | 8-K | ef20073066_8k.htm |
| 2026-05-08 | 10-Q | gyre-20260331.htm |
| 2026-05-07 | 8-K | gyre-20260507.htm |
| 2026-05-04 | DEFA14A | ef20072214_defa14a.htm |
| 2026-05-04 | 8-K | ef20072211_8k.htm |